Literature DB >> 19887897

Orphan nuclear receptor small heterodimer partner inhibits angiotensin II- stimulated PAI-1 expression in vascular smooth muscle cells.

Kyeong-Min Lee1, Hye-Young Seo, Mi-Kyung Kim, Ae-Kyung Min, Seong-Yeol Ryu, Yoon-Nyun Kim, Young Joo Park, Hueng-Sik Choi, Ki-Up Lee, Wan-Ju Park, Keun-Gyu Park, In-Kyu Lee.   

Abstract

Angiotensin II is a major effector molecule in the development of cardiovascular disease. In vascular smooth muscle cells (VSMCs), angiotensin II promotes cellular proliferation and extracellular matrix accumulation through the upregulation of plasminogen activator inhibitor-1 (PAI-1) expression. Previously, we demonstrated that small heterodimer partner (SHP) represses PAI-1 expression in the liver through the inhibition of TGF-beta signaling pathways. Here, we investigated whether SHP inhibited angiotensin II-stimulated PAI-1 expression in VSMCs. Adenovirus-mediated overexpression of SHP (Ad- SHP) in VSMCs inhibited angiotensin II- and TGF-beta-stimulated PAI-1 expression. Ad-SHP also inhibited angiotensin II-, TGF-beta- and Smad3-stimulated PAI-1 promoter activity, and angiotensin II-stimulated AP-1 activity. The level of PAI-1 expression was significantly higher in VSMCs of SHP(-/-) mice than wild type mice. Moreover, loss of SHP increased PAI-1 mRNA expression after angiotensin II treatment. These results suggest that SHP inhibits PAI-1 expression in VSMCs through the suppression of TGF-beta/Smad3 and AP-1 activity. Thus, agents that target the induction of SHP expression in VSMCs might help prevent the development and progression of atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19887897      PMCID: PMC2811817          DOI: 10.3858/emm.2010.42.1.002

Source DB:  PubMed          Journal:  Exp Mol Med        ISSN: 1226-3613            Impact factor:   8.718


  37 in total

1.  The orphan nuclear receptor SHP inhibits hepatocyte nuclear factor 4 and retinoid X receptor transactivation: two mechanisms for repression.

Authors:  Y K Lee; H Dell; D H Dowhan; M Hadzopoulou-Cladaras; D D Moore
Journal:  Mol Cell Biol       Date:  2000-01       Impact factor: 4.272

2.  PAI-1 and TGF-beta: unmasking the real driver of TGF-beta-induced vascular pathology.

Authors:  Douglas E Vaughan
Journal:  Arterioscler Thromb Vasc Biol       Date:  2006-04       Impact factor: 8.311

Review 3.  TGF-beta signaling in vascular fibrosis.

Authors:  Marta Ruiz-Ortega; Juan Rodríguez-Vita; Elsa Sanchez-Lopez; Gisselle Carvajal; Jesús Egido
Journal:  Cardiovasc Res       Date:  2007-02-12       Impact factor: 10.787

4.  Angiotensin II activates the Smad pathway in vascular smooth muscle cells by a transforming growth factor-beta-independent mechanism.

Authors:  Juan Rodríguez-Vita; Elsa Sánchez-López; Vanesa Esteban; Mónica Rupérez; Jesús Egido; Marta Ruiz-Ortega
Journal:  Circulation       Date:  2005-05-09       Impact factor: 29.690

5.  Multiple biomarkers for the prediction of first major cardiovascular events and death.

Authors:  Thomas J Wang; Philimon Gona; Martin G Larson; Geoffrey H Tofler; Daniel Levy; Christopher Newton-Cheh; Paul F Jacques; Nader Rifai; Jacob Selhub; Sander J Robins; Emelia J Benjamin; Ralph B D'Agostino; Ramachandran S Vasan
Journal:  N Engl J Med       Date:  2006-12-21       Impact factor: 91.245

6.  The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis.

Authors:  Stefano Fiorucci; Elisabetta Antonelli; Giovanni Rizzo; Barbara Renga; Andrea Mencarelli; Luisa Riccardi; Stefano Orlandi; Roberto Pellicciari; Antonio Morelli
Journal:  Gastroenterology       Date:  2004-11       Impact factor: 22.682

7.  Alpha-lipoic acid inhibits matrix metalloproteinase-9 expression by inhibiting NF-kappaB transcriptional activity.

Authors:  Hye-Soon Kim; Hye-Jin Kim; Keun-Gyu Park; Yoon-Nyun Kim; Taeg-Kyu Kwon; Joong-Yeol Park; Ki-Up Lee; Jung-Guk Kim; In-Kyu Lee
Journal:  Exp Mol Med       Date:  2007-02-28       Impact factor: 8.718

8.  Orphan nuclear receptor small heterodimer partner inhibits transforming growth factor-beta signaling by repressing SMAD3 transactivation.

Authors:  Ji Ho Suh; Jiansheng Huang; Yun-Yong Park; Hyun-A Seong; Dongwook Kim; Minho Shong; Hyunjung Ha; In-Kyu Lee; Keesook Lee; Li Wang; Hueng-Sik Choi
Journal:  J Biol Chem       Date:  2006-10-30       Impact factor: 5.157

9.  Orphan nuclear receptor small heterodimer partner represses hepatocyte nuclear factor 3/Foxa transactivation via inhibition of its DNA binding.

Authors:  Joon-Young Kim; Han-Jong Kim; Kyung Tae Kim; Yun-Yong Park; Hyun-A Seong; Ki Cheol Park; In-Kyu Lee; Hyunjung Ha; Minho Shong; Sang Chul Park; Hueng-Sik Choi
Journal:  Mol Endocrinol       Date:  2004-09-09

10.  Essential role of Smad3 in angiotensin II-induced vascular fibrosis.

Authors:  Wansheng Wang; Xiao R Huang; Ellery Canlas; Kazuhiro Oka; Luan D Truong; Chuxia Deng; Neil A Bhowmick; Wenjun Ju; Erwin P Bottinger; Hui Y Lan
Journal:  Circ Res       Date:  2006-03-23       Impact factor: 17.367

View more
  3 in total

1.  Insulin-dependent suppression of cholesterol 7α-hydroxylase is a possible link between glucose and cholesterol metabolisms.

Authors:  Wook Ha Park; Youngmi Kim Pak
Journal:  Exp Mol Med       Date:  2011-10-31       Impact factor: 8.718

2.  A Novel Systems-Biology Algorithm for the Analysis of Coordinated Protein Responses Using Quantitative Proteomics.

Authors:  Fernando García-Marqués; Marco Trevisan-Herraz; Sara Martínez-Martínez; Emilio Camafeita; Inmaculada Jorge; Juan Antonio Lopez; Nerea Méndez-Barbero; Simón Méndez-Ferrer; Miguel Angel Del Pozo; Borja Ibáñez; Vicente Andrés; Francisco Sánchez-Madrid; Juan Miguel Redondo; Elena Bonzon-Kulichenko; Jesús Vázquez
Journal:  Mol Cell Proteomics       Date:  2016-02-18       Impact factor: 5.911

3.  Inhibition of NF-κB prevents high glucose-induced proliferation and plasminogen activator inhibitor-1 expression in vascular smooth muscle cells.

Authors:  In Kyung Jeong; Da Hee Oh; Seung Joon Park; Ja Heon Kang; Sunshin Kim; Myung Shik Lee; Myung Jun Kim; Yoo Chul Hwang; Kyu Jeong Ahn; Ho Yeon Chung; Min Kyung Chae; Hyung Joon Yoo
Journal:  Exp Mol Med       Date:  2011-12-31       Impact factor: 8.718

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.